A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

Conditions:   Cancer;   Neuroendocrine Tumors;   NET;   Adrenocortical Carcinoma;   ACCIntervention:   Drug: TKM-080301Sponsor:   Tekmira Pharmaceuticals CorporationActive, not recruiting - verified May 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials